Semaglutide
Concentration calculator
Research summary
Semaglutide is a GLP-1 receptor agonist evaluated in large, randomized, placebo-controlled human clinical trials (the STEP program), published in peer-reviewed journals including the New England Journal of Medicine.
In the STEP 1 trial, adults with overweight or obesity receiving weekly semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks versus 2.4% with placebo, with results sustained to two years in the STEP 5 trial. Related STEP trials reported body-weight reductions in participants with heart failure with preserved ejection fraction and with knee osteoarthritis, with lifestyle intervention included in all study arms.
Sources: NEJM, 2021 (STEP 1); Nature Medicine, 2022 (STEP 5); NEJM, 2023 (STEP-HFpEF); NEJM, 2024 (STEP 9). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.
Decoding the Benefits
- Average weight loss cleared 14.9% over 68 weeks in the pivotal STEP 1 trial — more than six times the placebo result.
- Benefits held up at the two-year mark, and extended to heart-failure and knee-osteoarthritis patient groups in follow-on trials.
Customer reviews
More in Metabolic
